Cancers | Free Full-Text | PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
OlympiA Supports Use of Adjuvant Olaparib As a New Standard of Care for Select Patients With Early Breast Cancer
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM
Adjuvant olaparib prolongs survival for certain patients with early breast cancer
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | NEJM
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | NEJM
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 an
OlympiA trial | Lynparza | Astrazeneca
Inclusion criteria of the OlympiA study according to tumor subtype and... | Download Scientific Diagram
PDF) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Early Breast Cancer
OlympiA - Breast International Group
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Early Breast Cancer
Asco 2021 – full Olympia results sweep away Parp doubts | Evaluate
OlympiA Data Spur Update to ASCO Guideline on Hereditary Breast Cancer Treatment
Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer - The ASCO Post
Olaparib Added to Standard Treatment Boosts Survival in Patients with Inherited BRCA Mutations | Smolecule
OlympiA trial | Lynparza | Astrazeneca
Asco 2021 – full Olympia results sweep away Parp doubts | Evaluate
Paolo Tarantino on Twitter: "Adjuvant olaparib relevantly improved DFS in #OlimpyA, setting a new SoC for BRCA-mutant patients with EBC 🗓 Mark the date of March 16, not to miss this OlympiA
Shannon Westin on Twitter: "The OlympiA trial results are striking! Olaparib improved invasive and distant disease free survival in high risk #BRCA mutant #BreastCancer #gyncsm #bcsm #ASCO21 plenary starts off with a
